BRO Is Being Punished For A Sin That Doesn't Exist

Brown & Brown has become the market's favorite person to dislike, and honestly? The crowd is wrong.

The stock closed Tuesday around $70.90, up on the day, sitting well above its 200-day average after a brutal trailing year that's left it down roughly 21% over the past twelve months. It's lagged the S&P 500 by a country mile — that index is up mid-teens in the same window while BRO has been grinding lower. Wall Street is split so badly it looks like a coin flip between bulls and bears, with price targets ranging from Morgan Stanley's $55 down to a $90 highball. Earnings land this week, on October 26. So let me be direct about where I stand.

The bears have a real story, and it's not crazy. Organic revenue fell 0.7% in the second quarter — two straight quarters of organic decline — which forces the uncomfortable question: how much of this company's "growth" is just buying other companies and praying the integration sticks? Adjusted EBITDAC margin contracted 100 basis points in that quarter. Amortization more than doubled to roughly $110 million. Interest expense nearly doubled, up about 96% year over year to $100 million. Debt swelled to roughly $7.6 billion after the Accession deal. Parnassus walked away entirely, citing an "industry downturn" and a company working to close an AI gap versus bigger peers. That's not noise. That's a fund with a decent record packing up and leaving.

But here's what the bears are underweighting: the market is pricing BRO as if it's a leveraged M&A machine on the verge of a margin catastrophe, when the actual numbers tell a wildly different story.

Look at the balance sheet the desk is looking at right now. Debt-to-equity is 0.64, not the crushing leverage the bear thesis implies. Operating margin is sitting at 29.5%. Gross margin is a fat 92.6%. Forward P/E is 14.6 — you're paying 14.6 times forward earnings for a company with industry-leading cash flow conversion and four consecutive earnings beats. That is not a distressed-capital situation. That's a buyer's market for a quality compounder that had a rough stretch.

And the re-rating isn't a fantasy. In October alone, TD Cowen initiated coverage with a Buy and an $82 target, explicitly calling the stock undervalued and set for upward re-rating. KBW upgraded to Outperform at $77. Oppenheimer started at Outperform, $73. JPMorgan hiked its target to $83. Four real voices looking at the same filings I am and concluding the tape is cheap.

Now, don't mistake this for a unanimity argument. Goldman and Jefferies both cut targets. Morgan Stanley stays Underweight. But when you have TD Cowen at $82 and Morgan Stanley at $55 on the same tape, the truth isn't "$75 average target, no upside." The truth is that nobody here actually knows where BRO trades in six months, and the current price reflects a middle-to-lower reading of that debate.

The catalyst is next week. Q3 earnings drop October 26 after the close, with the call on the 27th. And the setup, frankly, has a nice asymmetry. Consensus is looking for EPS of roughly $1.08 on revenue near $1.76 billion — modest, low-single-digit year-over-year growth. Management has talked up favorable rate increases across most admitted lines, with casualty and auto rates still climbing. If a company can deliver mid-single-digit EPS growth and show organic revenue finally ticking positive after two down quarters, the street's reluctance evaporates fast. The stock has already popped — up over 10% in the past week, 8.4% in the quarter — which means some money is already betting on a good print.

The thing that gets me is the organic-growth scare. A negative 0.7% is not a free-cash-flow implosion. It's a broker taking a breath in a soft cycle. Brokers pass rate increases through; they don't eat them. The underwriting environment management described is improving, not deteriorating. The fear is that growth now requires acquisitions — but acquisition-driven growth at a 14.6x forward multiple is exactly what value investors buy, not what they flee.

So here's my view, plainly: BRO is a high-quality, cash-generative broker being dragged down by legitimate but overpriced fears. The bears are right that the growth machine needs fuel and the Accession integration carries real risk — the Oxford Risk Management litigation and the IRS 831(b) scrutiny are not things to gloss over. But you are not paying for distress at this multiple. You're paying 14.6 times forward earnings for a company that repurchased $250 million of stock in Q2, raising its dividend, and trading at a price 19% below where it was a year ago.

The asymmetry next week is what matters. A modest beat with a return to organic growth and this tape re-rates toward that $82 TD Cowen target with its eyes closed. A genuine organic collapse and the $55 crowd gets vindicated — but that requires the numbers to actually break, and nothing in the current balance sheet suggests they're about to.

I'd rather be on the buy side of that trade than the one convinced it's already right.